Ángel Carracedo: ''Only 50% of First-Line Drugs are Effective''
News Mar 20, 2013
Currently only 50% of first-line drugs are effective and adverse effects of drugs are the fourth leading cause of death in the United States and the eighth in Europe. According to Angel Carracedo "two individuals do not respond equal to a drug in health conditions, let alone in terms of disease. One of the factors that determine this response is genetics."
Knowing patient's genetics could allow administer only appropriate medications and save the patient from adverse effects of those drugs which wouldn't be effective. In fact, as explained Carracedo, the FDA and the EMEA (the drug regulatory agencies in the U.S. and Europe respectively) have made several recommendations in the data sheet of various drugs, especially in chemotherapy, so that it is mandatory genetic testing before prescribing them. However Carracedo has warned that "not all clinicians get this information and it is not always used properly."
"We must keep working," said Carracedo "in validating new biomarkers with an acceptable cost/effectiveness and find ways of implementing pharmacogenetics in the most efficient way in clinical practice."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018